ERβ localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations

ERβ Regulates NSCLC Phenotypes by Controlling Oncogenic RAS Signaling

(2014) Fotis Nikolos et al.   MOLECULAR CANCER RESEARCH

Cytoplasmic estrogen receptor β as a potential marker in human non-small cell lung carcinoma

(2012) Mohit Kumar Verma et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Combining the Multitargeted Tyrosine Kinase Inhibitor Vandetanib with the Antiestrogen Fulvestrant Enhances Its Antitumor Effect in Non-small Cell Lung Cancer

(2012) Jill M. Siegfried et al.   Journal of Thoracic Oncology

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

(2012) Rafael Rosell et al.   LANCET ONCOLOGY

Estrogen Receptors β1 and β2 Have Opposing Roles in Regulating Proliferation and Bone Metastasis Genes in the Prostate Cancer Cell Line PC3

(2012) Prasenjit Dey et al.   MOLECULAR ENDOCRINOLOGY

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

(2011) Caicun Zhou et al.   LANCET ONCOLOGY

Potential Clinical Significance of a Plasma-Based KRAS Mutation Analysis in Patients with Advanced Non-Small Cell Lung Cancer

(2010) S. Wang et al.   CLINICAL CANCER RESEARCH

Estrogen receptor β2 and β5 are associated with poor prognosis in prostate cancer, and promote cancer cell migration and invasion

(2010) Yuet-Kin Leung et al.   ENDOCRINE-RELATED CANCER

Expression of estrogen receptor beta predicts a clinical response and longer progression-free survival after treatment with EGFR–TKI for adenocarcinoma of the lung

(2010) Naohiro Nose et al.   LUNG CANCER

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Estrogen Receptor β Exerts Tumor Repressive Functions in Human Malignant Pleural Mesothelioma via EGFR Inactivation and Affects Response to Gefitinib

(2010) Giulia Pinton et al.   PLoS One

Epidermal Growth Factor Receptor Mutations in Plasma DNA Samples Predict Tumor Response in Chinese Patients With Stages IIIB to IV Non–Small-Cell Lung Cancer

(2009) Hua Bai et al.   JOURNAL OF CLINICAL ONCOLOGY

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

(2009) Tetsuya Mitsudomi et al.   LANCET ONCOLOGY

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Estrogen Receptor Signaling in Lung Cancer

(2009) Jill M. Siegfried et al.   SEMINARS IN ONCOLOGY

Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer

(2008) Anne M. Traynor et al.   LUNG CANCER

Estrogen Receptor β Functions through Nongenomic Mechanisms in Lung Cancer Cells

(2008) GuangFeng Zhang et al.   MOLECULAR ENDOCRINOLOGY